157 related articles for article (PubMed ID: 18157525)
1. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes.
Djordjevic N; Ghotbi R; Bertilsson L; Jankovic S; Aklillu E
Eur J Clin Pharmacol; 2008 Apr; 64(4):381-5. PubMed ID: 18157525
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.
Ghotbi R; Christensen M; Roh HK; Ingelman-Sundberg M; Aklillu E; Bertilsson L
Eur J Clin Pharmacol; 2007 Jun; 63(6):537-46. PubMed ID: 17370067
[TBL] [Abstract][Full Text] [Related]
3. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.
Djordjevic N; Ghotbi R; Jankovic S; Aklillu E
Eur J Clin Pharmacol; 2010 Jul; 66(7):697-703. PubMed ID: 20390257
[TBL] [Abstract][Full Text] [Related]
4. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Gunes A; Ozbey G; Vural EH; Uluoglu C; Scordo MG; Zengil H; Dahl ML
Pharmacogenomics; 2009 May; 10(5):769-78. PubMed ID: 19450128
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
[TBL] [Abstract][Full Text] [Related]
7. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
Bock KW; Schrenk D; Forster A; Griese EU; Mörike K; Brockmeier D; Eichelbaum M
Pharmacogenetics; 1994 Aug; 4(4):209-18. PubMed ID: 7987405
[TBL] [Abstract][Full Text] [Related]
8. Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.
Alarcan H; Cannet P; Camus V; Fond G; Zendjidjian X; Guilhaumou R; Quaranta S
Br J Clin Pharmacol; 2023 May; 89(5):1665-1671. PubMed ID: 36507652
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of CYP1A2 and CYP2A6 activity: phenotypes and the effect of age and sex in a Nigerian population.
Adehin A; Bolaji OO
Drug Metab Pers Ther; 2015 Sep; 30(3):203-10. PubMed ID: 26098700
[TBL] [Abstract][Full Text] [Related]
10. CYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancer.
Pavanello S; Mastrangelo G; Placidi D; Campagna M; Pulliero A; Carta A; Arici C; Porru S
Eur J Epidemiol; 2010 Jul; 25(7):491-500. PubMed ID: 20559687
[TBL] [Abstract][Full Text] [Related]
11. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2.
Han XM; Ou-Yang DS; Lu PX; Jiang CH; Shu Y; Chen XP; Tan ZR; Zhou HH
Pharmacogenetics; 2001 Jul; 11(5):429-35. PubMed ID: 11470995
[TBL] [Abstract][Full Text] [Related]
12. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility.
Dobrinas M; Cornuz J; Oneda B; Kohler Serra M; Puhl M; Eap CB
Clin Pharmacol Ther; 2011 Jul; 90(1):117-25. PubMed ID: 21593735
[TBL] [Abstract][Full Text] [Related]
13. Association of coffee consumption and CYP1A2 polymorphism with risk of impaired fasting glucose in hypertensive patients.
Palatini P; Benetti E; Mos L; Garavelli G; Mazzer A; Cozzio S; Fania C; Casiglia E
Eur J Epidemiol; 2015 Mar; 30(3):209-17. PubMed ID: 25595320
[TBL] [Abstract][Full Text] [Related]
14. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity.
Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E
Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287
[TBL] [Abstract][Full Text] [Related]
15. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
[TBL] [Abstract][Full Text] [Related]
16. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.
Plowchalk DR; Rowland Yeo K
Eur J Clin Pharmacol; 2012 Jun; 68(6):951-60. PubMed ID: 22258279
[TBL] [Abstract][Full Text] [Related]
17. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
[TBL] [Abstract][Full Text] [Related]
18. Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls.
Petersen MS; Halling J; Damkier P; Nielsen F; Grandjean P; Weihe P; Brøsen K
Eur J Clin Pharmacol; 2006 Dec; 62(12):1041-8. PubMed ID: 17089110
[TBL] [Abstract][Full Text] [Related]
19. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers.
Schrenk D; Brockmeier D; Mörike K; Bock KW; Eichelbaum M
Eur J Clin Pharmacol; 1998 Jan; 53(5):361-7. PubMed ID: 9516038
[TBL] [Abstract][Full Text] [Related]
20. Human cytochrome P4501A2.
Landi MT; Sinha R; Lang NP; Kadlubar FF
IARC Sci Publ; 1999; (148):173-95. PubMed ID: 10493258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
